AcquisitionOther

First Wave BioPharma, Inc. acquired ImmunogenX

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

First Wave BioPharma, Inc. -> ImmunogenX

First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.

Open source record (SEC) ↗